Cargando…
Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer
Neoadjuvant chemotherapy is given before surgery to patients with primarily unresectable, advanced-stage cancers to render the tumor resectable, and to facilitate breast conservation. Previously, we have reported a prospective phase II trial for women with stage IIA-B/IIIA-B-C breast cancer with imp...
Autores principales: | Hsu, Ping-Ching, Kadlubar, Susan A., Siegel, Eric R., Rogers, Lora J., Todorova, Valentina K., Su, L. Joseph, Makhoul, Issam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7162481/ https://www.ncbi.nlm.nih.gov/pubmed/32298288 http://dx.doi.org/10.1371/journal.pone.0230248 |
Ejemplares similares
-
Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients
por: Makhoul, Issam, et al.
Publicado: (2017) -
Relevance of Pathological Complete Response after Neoadjuvant Therapy for Breast Cancer
por: Pennisi, Angela, et al.
Publicado: (2016) -
Genome-Wide DNA Methylation Signatures Predict the Early Asymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer
por: Bauer, Michael A., et al.
Publicado: (2021) -
Circulating Exosomal microRNAs as Predictive Biomarkers of Neoadjuvant Chemotherapy Response in Breast Cancer
por: Todorova, Valentina K., et al.
Publicado: (2022) -
Association of DNA-Methylation Profiles With Immune Responses Elicited in Breast Cancer Patients Immunized With a Carbohydrate-Mimicking Peptide: A Pilot Study
por: Hernandez Puente, Cinthia Violeta, et al.
Publicado: (2020)